Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?

Pfizer’s $43 billion Seagen acquisition became  symbolic of its post-COVID spending spree. The acquisition gave the company an established oncology business and a deeper antibody-drug conjugate portfolio just as investors were grappling with the sharp decline of its COVID vaccine and Paxlovid sales. Fast forward to today, and now Lilly is on its own buying… The post Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate? appeared first on Drug Discovery and Development.

Continue reading →